Eligible patients 10 to 17 years of age were treated with metformin (at a dose of
1000 mg twice daily) to attain a glycated hemoglobin level of less than 8% and were
randomly assigned to continued treatment with metformin alone or to metformin
combined with rosiglitazone (4 mg twice a day) or a lifestyle-intervention program
focusing on weight loss through eating and activity behaviors. The primary outcome
was loss of glycemic control, defined as a glycated hemoglobin level of at least 8% for
6 months or sustained metabolic decompensation requiring insulin.